Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.

UCLA Med Center's Dr. Eddie Garon discusses the open question of the optimal duration of ongoing treatment with immunotherapy for lung cancer.

Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely to use these agents instead of or in combination with standard chemotherapy soon.

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines oligometastatic lung cancer and describes the recent trend toward the use of stereotactic body radiation therapy to treat it.

Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.

We recently joined a number of top faculty in the area of hematology in Whistler BC, for the 3rd Annual Summit on Hematologic Malignancies.Jennifer Brown, MD, PhD, Director of the CLL Center at the Dana-Farber Cancer Institute spoke with GRACE and provided provoking and educational discussions on

GRACE joined a number of top faculty in the area of hematology in Whistler BC, for the 3rd Annual Summit on Hematologic Malignancies. Jennifer Brown, MD, PhD, Director of the CLL Center at the Dana-Farber Cancer Institute spoke with GRACE and provided a provoking and educational discussion on FCR vs

GRACE joined a number of top faculty in the area of hematology in Whistler BC, for the 3rd Annual Summit on Hematologic Malignancies. Joshua Brody, MD, Oncologist and Director, Assistant Professor of Medicine, Hematology & Medical Oncology at Mount Sinai Hospital spoke with GRACE about the question

GRACE joined a number of top faculty in the area of hematology in Whistler BC, for the 3rd Annual Summit on Hematologic Malignancies. John Kuruvilla, MD, Associate Professor, Princess Margaret Hospital, University Health Network in Toronto, Canada, spoke with GRACE about Chronic Lymphocytic Leukemia

Stephen Liu, MD provides updates to our Lung Cancer Video Library. In this recent video, Dr. Liu discusses Continuing Immunotherapy Beyond Progression-In Which Patients Is This Appropriate

Lung Cancer Video Library 2018

Dr. H. Jack West, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, President and CEO of GRACE offers updates to our Lung Cancer Video Library.In this video, Dr. West discusses whether immunotherapy works in patients with driver mutations like EGFR and ALK.We thank the following

Lung Cancer Video Library 2018

Dr. H. Jack West, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, President and CEO of GRACE offers updates to our Lung Cancer Video Library.In this video, Dr. West discusses chemotherapy and immunotherapy combinations in advanced squamous non-small cell lung cancer. We thank

Jack West, MD, President and CEO of GRACE provides updates to our Lung Cancer Video Library. In this recent video, Dr. West discusses if immunotherapy should stop in responding patients after a fixed duration of treatment.

Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses the role for immunotherapy in patients with a driver mutation.

Dr. Karen Reckamp, MD, MS, City of Hope Comprehensive Cancer Center in Duarte, California joined GRACE to discuss the role of immunotherapy for previously treated patients with non-small cell lung cancer.